BioLife Solutions, Inc. (BLFS) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Non-GAAP) | 6.18M | FY2026-Q1 |
| Adjusted Gross Margin (Non-GAAP) | 64.00 percent | FY2026-Q1 |
| Gross Margin (GAAP) | 64.00 percent | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization Margin (Non-GAAP) | 22.00 percent | FY2026-Q1 |
| Adjusted Net Loss From Continuing Operations (Non-GAAP) | 2.1M | FY2026-Q1 |
| Adjusted Operating Income (Loss) From Continuing Operations (Non-GAAP) | 1M | FY2026-Q1 |
| Embedded Unique Commercial Cell and Gene Therapy Products | 17.00 | FY2026-Q1 |
| Biopreservation Media Used in Ongoing Commercially Sponsored Clinical Trials in the United States | 250.00 | FY2026-Q1 |
| Biopreservation Media Market Share in Ongoing Commercially Sponsored Clinical Trials (United States) | 70.00 percent | FY2026-Q1 |
| Clinical Trials Using CellSeal Vials and Human Platelet Lysate Products | 35.00 | FY2026-Q1 |
| Phase Three Clinical Trials Using Biopreservation Media | 30.00 | FY2026-Q1 |
| Evo and Thaw Platform Revenue 2025 Guidance | 2.7M | FY2025-Q3 |
| Approved Cell and Gene Therapy Products With Embedded Biopreservation Media | 4.00 | FY2025-Q1 |
| Cumulative U.S. Food and Drug Administration Master File Cross-References Processed | 782.00 | FY2025-Q1 |
Back to BLFS overview · BLFS earnings · BLFS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.